A comparative study between full-dose and half-dose intravesical immune bacille Calmette–Guérin injection in the management of superficial bladder cancerFootnote

Peer review under responsibility of Arab Association of Urology.

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN. Cancer incidence and mortality worldwide: IARC CancerBase no. 10, 2008 [Internet]. Lyon, France: International Agency for Research on Cancer. Available at http://globocan.iarc.fr; 2010 [accessed 6 May, 2012].
   Google Scholar
• S.MalkowiczJ.Bruce Vaugh DavidA.J.WeinAdult genitourinary cancer – prostate and bladderP.M.HannoPenn Clinical Manual of Urology2007SaundersPhiladelphia523570 Ch. 15
   Google Scholar
• J.OddensM.BrausiR.SylvesterW.J.KirkelsC.van de BeekG.van Andelet alFinal results of an EORTCGU Cancers Group Randomized Study of maintenance bacillus Calmette–Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder. One-third dose versus full dose and 1 year versus 3 years of maintenanceEur Urol632013247
   Web of Science ®Google Scholar
• M.BabjukW.OosterlinckR.SylvesterE.KaasinenA.BöhleJ.Palou-Redortaet alEAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 updateEur Urol5920119971008
   PubMed Web of Science ®Google Scholar
• T.P.KresowikT.S.GriffithBacillus Calmette–Guerin immunotherapy for urothelial carcinoma of the bladderImmunotherapy142009281288
   Google Scholar
• P.GonteroA.BohleP.U.MalmstromM.A.O’DonnellM.OderdaR.Sylvesteret alThe role of bacillus Calmette–Guerin in the treatment of non-muscle-invasive bladder cancerEur Urol57201002
   Web of Science ®Google Scholar
• D.P.WoodUrothelial tumors of the bladderA.J.WeinL.R.KavoussiA.C.Noviket alCampbell-Walsh Urology10th ed.62012Saunders, Elsevier23092333
   Google Scholar
• D.LammR.PersadM.ColombelM.BrausMaintenance Bacillus Calmette–Guerin. The standard of care for the prophylaxis and management of intermediate-and high-risk non muscle-invasive bladder cancerEur Urol Supp922010715734
   Google Scholar
• O.R.KarabacakE.CakmakciU.OzturkF.DemirelA.DilliB.Hekimogluet alVirtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopyCan Urol Assoc J520113437
   Web of Science ®Google Scholar
• A.S.FelixA.S.SolimanH.KhaledM.S.ZaghloulM.BanerjeeM.El-Baradieet alThe changing patterns of bladder cancer in Egypt over the past 26 yearsCancer Causes Control192008421429
   PubMed Web of Science ®Google Scholar
• M.S.AgrawalM.AgrawalS.BansalM.AgarwalP.LavaniaJ.GoyalThe safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinomaEur Urol542007303314
   Google Scholar
• C.W.ChengM.T.NgS.Y.ChanW.H.SunLow dose BCG as adjuvant therapy for superficial bladder cancer and literature reviewANZ J Surg742004569572
   Web of Science ®Google Scholar
• A.R.LosaA.HurleLembo: low-dose BCG for carcinoma in situ of the bladder: long-term resultsJ Urol16320006872
   PubMed Web of Science ®Google Scholar
• P.BassiR.SpinadinR.CarandoG.BaltaF.PaganoModified induction course: a solution to side-effects?Eur Urol37Suppl. 120003132
   Google Scholar
• F.PaganoP.BassiN.PiazzaImproving the efficacy of BCG immunotherapy by dose reductionEur Urol27Suppl. 119951922
   Google Scholar
• J.A.Martínez-PiñeiroN.FloresS.IsornaE.SolsonaJ.L.SebastiánC.Pertusaet alLong-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette–Guerin with a reduced dose of 27 mg in superficial bladder cancerBJU Int892002671680
   PubMed Web of Science ®Google Scholar
• J.A.Martínez-PiñeiroL.Martínez-PiñeiroE.SolsonaR.H.RodríguezJ.M.GómezM.G.Martínet alHas a 3-fold decreased dose of BCG the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trialJ Urol174200512421247
   PubMed Web of Science ®Google Scholar
• A.IrieT.UchidaH.YamashitaK.MatsumotoT.SatohH.Kohet alSufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette–Guérin for superficial bladder cancer recurrenceInt J Urol102003183189
   PubMed Web of Science ®Google Scholar
• H.YariM.FallahnezhadB.Haji KarimS.Tavasoli ShirvanComparison of full-dose intravesical BCG versus half dose BCG and Mitomycin-C in treatment of patients with superficial bladder cancerEur Urol Suppl92010595
   Web of Science ®Google Scholar
• A.KumarD.DubeyP.BansalA.MandahaniS.NaikUrinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette–Guerin (modified Danish 1331 Strain) for superficial bladder cancerJ Urol168200222322235
   Web of Science ®Google Scholar
• D.MackW.HoltlP.BassiM.BrausiP.FerrariC.Balincourtet alThe ablative effect of quarter dose BCG on a papillary marker lesion of the bladderJ Urol1652001401403
   Web of Science ®Google Scholar
• D.MackJ.FrickLow-dose bacille Calmette–Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase11 study with the BCG strain Connaught CanadaBr J Urol751995185
   Google Scholar
• R.A.HurleA.LosaP.RanieriA.GraziottiLembo: low dose Pasteur bacillus Calmette–Guerin regimen in stage T1, Grade 3 bladder cancer therapyJ Urol156199616021605
   Web of Science ®Google Scholar
• A.MoralesD.EidingerA.W.BruceIntracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumorsJ Urol1161976180183
   PubMed Web of Science ®Google Scholar
• A.OjeaJ.L.NogueiraE.SolsonaN.FloresJ.M.GómezJ.R.Molinaet alA multicenter, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette–Guerin (27 mg) vs. very low-dose bacillus Calmette–Guerin (13.5 mg) vs mitomycin CEur Urol52200713981406
   PubMed Web of Science ®Google Scholar